CIDeRGeneral Information:
| Id: | 2,046 (click here to show other Interactions for entry) |
| Diseases: |
Diabetes mellitus, type II
- [OMIM]
Insulin resistance |
| Mus musculus | |
| genetically diabetic C57BL/KSJ db/db mouse | |
| BTO:0000991 pancreatic islet | |
| article | |
| Reference: | Cheng Q et al.(2008) Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2-(1H-tetrazol-5-yl)-[1,1-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J. Pharmacol. Exp. Ther. 327: 683-691 [PMID: 18787107] |
Interaction Information:
| Comment | Glucose-stimulated insulin release was significantly reduced in islets from obese db/db mice, compared with the control mice. Exendin-4 and valsartan significantly doubled glucose-induced insulin release of db/db isolated islets. A clear synergetic effect was observed with the combination to the extent that these levels were comparable with those in normal m/db islets. |
|
Formal Description Interaction-ID: 16371 |
drug/chemical compound increases_activity of process |